4DMT In The Media

4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremia

Emeryville, CA – November 16, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that the U.S. Food and Drug Administration (FDA) has ...

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

Emeryville, CA, April 30, 2018 — 4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced the expansion of its 2015 research agreement with F. Hoffmann-La Roche ...

4D Molecular Therapeutics to present at 2017 Cell & Gene Meeting on the Mesa

Emeryville, CA, October 4, 2017 – 4D Molecular Therapeutics announced today that David Kirn, MD, co-founder, Chairman & CEO will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October ...

4D Molecular Therapeutics Profiled in BioCentury

BioCentury, a leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government, has published an Emerging Company Profile on 4D Molecular Therapeutics. Co-founders David Schaffer and David Kirn discuss AAV gene therapy, the ...

4DMT Featured in Nature Medicine Article

In September 2015, Nature Medicine featured 4D Molecular Therapeutics in an article entitled “Starting up and spinning out: The changing nature of partnerships between pharma and academia”. The article describes the evolving variety of forms that can be taken for collaborations between ...

Pfizer Expands R&D Equity Investment Strategy to Access Early-Stage Scientific Innovations

Initial Investments in Companies Focused on Conditionally Active Biologics, Immuno-Oncology, Neurodegenerative Technologies and Gene Therapy Provide Access to Pfizer Resources to Help Accelerate Research into Novel Pathways and Technologies January 08, 2016 04:13 PM Eastern Standard Time NEW YORK–(BUSINESS ...

4DMT Featured in Biotech Documentary

French film company, LaBiotech Tour, recently featured 4D Molecular Therapeutics in their documentary on Bay Area biotech companies. LaBiotech Tour is the first World Tour of Biotech ecosystems, showcasing companies from India to Germany to Ireland. LaBiotech selected 4DMT to ...

4D Mentioned in Nature Article

“Starting up and Spinning out: The changing nature of partnerships between big pharma and academia” VOLUME 21 | NUMBER 9 | SEPTEMBER 2015 NATURE MEDICINE “The inception of 4D Molecular Therapeutics is another example of how startups are spinning out ...

Co-Founder David Schaffer Presents AAV Directed Evolution Research

4D Molecular Therapeutics co-founder, Dr. David Schaffer, recently presented  an overview of his research entitled “Directed evolution of novel adeno-associated viral vectors for gene therapy” as a contribution to the Henry Stewart Talk Series titled “Gene Transfer and Gene Therapy”, part of ...

Catalyst Magazine: Gene therapy’s second wave

In retrospect, the 1990s appear to have been gene therapy’s lost decade. Then, the idea that common diseases could be cured by repairing underlying defects in our genetic information had probably become too appealing. New cures seemed just around the ...

Genes Get in Your Eye

Using mouse eyes as a setting for directed evolution, scientists have created a new version of the gene therapy vector adeno-associated virus (AAV) that can deliver genes deep into the retina, according to a paper published online today (June 12) ...